Literature DB >> 12039807

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Peter Jüni, Anne W S Rutjes, Paul A Dieppe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039807      PMCID: PMC1123260          DOI: 10.1136/bmj.324.7349.1287

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J M Wright; T L Perry; K L Bassett; G K Chambers
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

3.  Researchers deny any attempt to mislead the public over JAMA article on arthritis drug.

Authors:  S Gottlieb
Journal:  BMJ       Date:  2001-08-11

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

6.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

  6 in total
  81 in total

1.  Potential alternatives to COX 2 inhibitors.

Authors:  M M Skelly; C J Hawkey
Journal:  BMJ       Date:  2002-06-01

Review 2.  Selective COX-2 inhibitors: a health economic perspective.

Authors:  David L B Schwappach; Christian M Koeck
Journal:  Wien Med Wochenschr       Date:  2003

3.  Failures of the therapeutic chain as a cause of drug ineffectiveness.

Authors:  Albert Figueras; Joan-Ramon Laporte
Journal:  BMJ       Date:  2003-04-26

4.  Why don't we initiate more large simple randomized controlled trials?

Authors:  James M Wright
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

5.  Drug company sues Spanish bulletin over fraud claim.

Authors:  Liza Gibson
Journal:  BMJ       Date:  2004-01-24

6.  Non-surgical treatment of osteoarthritis: a half century of "advances".

Authors:  K D Brandt
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

7.  Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.

Authors:  Peter Juni; Rebekka Sterchi; Paul Dieppe
Journal:  BMJ       Date:  2003-02-08

8.  US Food and Drug Administration gets it right.

Authors:  Matthew L Grove
Journal:  BMJ       Date:  2002-10-05

9.  New dogmas or old?

Authors:  B J R Whittle
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial.

Authors:  U K Misra; M Jose; J Kalita
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.